Calendar

An AMCP and Milliman Corporate Training Program

Join leading managed care and health plan experts for an interactive training that translates medical benefit management into new opportunities for you and your customers. With AMCP faculty and Milliman professionals, you will receive: 

• An interactive self-paced e-Learning training program designed to fit into your busy schedule and deliver the basics with eight 40-minute modules.  This program is designed to deliver the fundamental knowledge on the basics of medical benefits medication management. The program includes an overview of today’s key trends and challenges and provides insights and solutions. 

• One day remote learning training from experts in managed care and health plans to gain knowledge and actionable insights in medical benefits medication management.  

The role of digital therapies in preventing, managing, and treating medical conditions has evolved greatly in the past few years. They may be used independently or taken in tandem with other therapies to optimize clinical outcomes for patients. As innovative therapies are introduced into the market, challenges with developing evidence-based coverage criteria and tracking utilization have been identified. Forum participants will outline key barriers and develop solutions to support the appropriate use and coverage of digital therapeutics in the health care system.

This event is invitation only. If you're interested in participating, please email corpopportunities@amcp.org.

An AMCP and Precision Value & Health Corporate Training Program

Over the last four –to five years, the market has seen the launch of numerous cell and gene therapies including Yescarta, Kymriah, Luxterna, and Zolgensma to name a few. The market for cell and gene therapy is poised to expand exponentially with over 1,100 cell and gene therapy companies who are actively conducting over 1,000 clinical trials.

Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies and can even differ between cell and gene therapy. These differences will impact how innovators develop evidence, manufacturing, and distribution capabilities and payers assess value, make coverage decisions and manage reimbursement.

Our half-day course will provide foundational information to equip the audience with how to best develop a compelling evidence package for cell and gene therapies, how payers will apply their assessment in decision-making, and how to best bridge the gap between these two. The program will be structured with a mixture of presentations and panel discussions.

An AMCP and Optum® Advisory Services Training Program

An AMCP and Valuate Health Training Program.

As the healthcare landscape evolves to deliver on the promises of value-based care, integrated delivery networks (IDNs) have emerged as a dominant institutional care model in the US market. Meanwhile, biopharmaceutical manufacturers have struggled to understand the needs of IDNs and how to engage with them in a meaningful way. A comprehensive understanding of IDN needs and priorities is critical in developing relevant support programs and resources that will drive true partnerships. These organizations are not just powerful in terms of market share, but also in the ever-growing space of value-based contracting. It is critical to understand the diverse behaviors and needs of each unique IDN in order to use your team’s resources efficiently and effectively. By taking a number of customer engagement steps, manufacturers can build a strategy for effective IDN engagement.

An AMCP and Milliman Corporate Training Program

The specialty pharmacy supply chain is complex. As the percentage of health care cost on specialty pharmacy increases, so does the number of stakeholders seeking solutions to reduce cost. Makers of specialty pharmaceuticals are contending with specialty distributors, specialty pharmacies, and health care providers who are all competing for a dominant position in drug delivery and reimbursement. Increasingly, influence from non-supply chain participants is shaping future considerations for specialty pharmaceutical manufacturers. These factors, as well as an increase in the number of high-cost therapies, incentivize employers, PBMs, manufacturers, and other stakeholders to reassess their business models and contracting arrangements for distribution and reimbursement.

Join us to hear managed care experts explore specialty pharmacy supply chain strategies, including motivations and challenges associated with various sourcing options across the pharmacy and medical benefit. Gaining a better understanding of the opportunities and challenges that come with the specialty pharmacy supply chain will be imperative in adapting successfully to this evolving pharmaceutical landscape.

Drug development is expensive, time consuming, and risky. To address these factors, clinical and regulatory experts in pharmaceutical companies must design drug development programs and clinical trials that meet FDA requirements. Especially with drugs approved via expedited pathways, the payers’ perspective typically takes a back seat to FDA approval criteria. Further, payer expectations for efficacy and safety, as well as population parameters, can differ from those established to meet FDA stipulations. However, meeting payers’ expectations is critical for patient access and commercial success. Payers increasingly demand demonstration of long-term value, especially for high investment medications or those with a high-risk safety profile. Despite the rigorous steps in the process of drug development, limitations exist due to the difference between FDA approval requirements and payer evidence needs. Forum participants will outline payer needs, barriers, and solutions for products approved through an expedited approval process regarding evidence for new drug products.

This event is invitation-only. If you're interested in participating, please email corpopportunities@amcp.org.

An AMCP and Xcenda Corporate Training Program.

This program offers real-world, relevant training for life science companies. Are your company’s pre-approval information exchange (PIE) strategy and tactics aligned with the market and FDA guidance? Do you know: 

• What PIE data payers are receiving about new products in development? 
• What additional data payers are looking for? 
• What additional information are payers providing about specialty products? 
• How other manufacturers are communicating PIE information? 
• How to leverage FormularyDecisions^SM for pre-approval communication? 
• How to integrate a pre-approval dossier into a proactive communications plan? 
• How to facilitate alignment on PIE policies and process with key stakeholders within your company ?